Program
rozanolixizumab
Also written as “Rozanolixizumab”, “UCB7665” and “UCB7665 Intravenous 1”.
Its studies are mostly in Myasthenia Gravis · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease · Fibromyalgia, led by UCB.
Drug pageRozanolixizumab: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 235 open or running | phase 4since Nov 17, 2025 | Aug 18, 2014 | May 6, 2027phase 3 · NCT05063162 |
Also a collaborator on its studies: Parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 10 earlier studies, Aug 18, 2014 to Jan 8, 2020.
- Jun 9, 2016Named rozanolixizumabINNProposed as its International Nonproprietary Name in WHO's List 115 · before, UCB7665
- Oct 15, 2020Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT04596995 · 43 enrolled · United States, China, Georgia and more
- Nov 5, 2020Phase 3 study in Myasthenia GravisNCT04650854 · 165 enrolled · United States, Canada, Czechia and more
- Mar 30, 2021Phase 1 study in Healthy Study ParticipantsNCT04828343 · 32 enrolled · United Kingdom
- May 3, 2021Phase 2 study in Leucine-Rich Glioma Inactivated 1 Autoimmune EncephalitisNCT04875975 · 12 enrolled · United States, Australia, Belgium and more
- Sep 21, 2021Phase 3 study in Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseNCT05063162 · 113 enrolled · United States, Australia, Belgium and more
- Nov 30, 2022Phase 2 study in FibromyalgiaNCT05643794 · 63 enrolled · United Kingdom
- Jan 4, 2023Phase 3 study in Myasthenia GravisNCT05681715 · 62 enrolled · United States, Canada, Georgia and more
- Sep 25, 2023Phase 3 study in Myasthenia GravisNCT06149559 · 14 enrolled · Italy, Japan, Poland and more
- Jul 22, 2024Phase 3 study in Myasthenia GravisNCT06540144 · 13 enrolled · Italy, Japan, Poland and more
- Dec 2, 2024Phase 1 study in Healthy ParticipantsNCT06720714 · 15 enrolled · United States
- Nov 17, 2025Phase 4 study in Myasthenia GravisNCT07246564 · 40 enrolled · China
- Mar 5, 20262 phase 3 studies in Myasthenia GravisNCT07463521, NCT07465289
- Oct 16, 2026Primary completion moved from 2027-08-17 to 2027-10-05Date moved laterphase 3 · +2 months · NCT06540144
- Oct 27, 2026Primary completion moved from 2031-01-23 to 2031-03-17Date moved laterphase 3 · +2 months · NCT07465289
Ahead
- May 6, 2027Primary completion: phase 3 study in Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseNCT05063162
- Oct 5, 2027Primary completion: phase 3 study in Myasthenia GravisNCT06540144
- Oct 15, 2027Primary completion: phase 4 study in Myasthenia GravisNCT07246564
- Dec 1, 2028Primary completion: phase 3 study in Myasthenia GravisNCT07463521
TargetBeta
“IgG receptor FcRn large subunit p51 inhibitor”ChEMBL 37, by rule
Other programs on FCGRT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efgartigimod alfarule | argenx | phase 4 | 48 |
| nipocalimabrule | Johnson & Johnson | phase 3 | 24 |
| batoclimabrule | immunovant-sciences-gmbh | phase 3 | 18 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07465289Myasthenia Gravis · United States, China, France and more | 3 | Recruiting | Mar 17, 2031 | 100 |
| NCT07463521Myasthenia Gravis · United States, Canada, China and more | 3 | Recruiting | Dec 1, 2028 | 120 |
| NCT07246564Myasthenia Gravis · China | 4 | Active, not recruiting | Oct 15, 2027 | 40 |
| NCT06720714Healthy Participants · United States | 1 | Completed | May 12, 2025 | 15 |
| NCT06540144Myasthenia Gravis · Italy, Japan, Poland and more | 3 | Active, not recruiting | Oct 5, 2027 | 13 |
| NCT06149559Myasthenia Gravis · Italy, Japan, Poland and more | 3 | Completed | Oct 5, 2026 | 14 |
| NCT05681715Myasthenia Gravis · United States, Canada, Georgia and more | 3 | Completed | Apr 23, 2024 | 62 |
| NCT05643794Fibromyalgia · United Kingdom | 2 | Completed | May 28, 2024 | 63 |
| NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease · United States, Australia, Belgium and more | 3 | Active, not recruiting | May 6, 2027 | 113 |
| NCT04875975Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis · United States, Australia, Belgium and more | 2 | Terminated | Mar 8, 2024 | 12 |
| NCT04828343Healthy Study Participants · United Kingdom | 1 | Completed | Apr 11, 2022 | 32 |
| NCT04650854Myasthenia Gravis · United States, Canada, Czechia and more | 3 | Completed | Jan 25, 2024 | 165 |
| NCT04596995Purpura, Thrombocytopenic, Idiopathic · United States, China, Georgia and more | 3 | Terminated | Dec 21, 2022 | 43 |
| NCT04224688Purpura, Thrombocytopenic, Idiopathic · United States, Bulgaria, China and more | 3 | Terminated | Apr 25, 2022 | 30 |
| NCT04200456Purpura, Thrombocytopenic, Idiopathic · United States, Bulgaria, France and more | 3 | Terminated | Mar 21, 2022 | 33 |
| NCT04124965Myasthenia Gravis · United States, Canada, Czechia and more | 3 | Completed | Sep 1, 2021 | 71 |
| NCT04051944Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Belgium, Denmark and more | 2 | Completed | Nov 10, 2021 | 21 |
| NCT03971422Myasthenia Gravis · United States, Belgium, Canada and more | 3 | Completed | Aug 31, 2021 | 200 |
| NCT03861481Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Belgium, Denmark and more | 2 | Completed | Mar 31, 2021 | 34 |
| NCT03859219Healthy-volunteers · United Kingdom | 1 | Completed | Apr 28, 2020 | 65 |
| NCT03052751Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Completed | May 31, 2018 | 43 |
| NCT02718716Thrombocytopenia · Australia, Bulgaria, Czechia and more | 2 | Completed | Feb 4, 2019 | 66 |
| NCT02220153Healthy · United Kingdom | 1 | Completed | Sep 2015 | 41 |
How it is read
Names in the registry
- “Rozanolixizumab”, 16 entries
- “rozanolixizumab”, 4 entries
- “UCB7665”, 2 entries
- “UCB7665 Intravenous 1”, 1 entry
- “UCB7665 Intravenous 2”, 1 entry
Conditions, from the studies’ own filings
- Myasthenia Gravis, 10 studies
- Purpura, Thrombocytopenic, Idiopathic, 3 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 2 studies
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, 1 study
- Fibromyalgia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.